Nick is a partner in our life sciences and chemistry team in London.
His practice concentrates on pharmaceutical chemistry, regenerative medicine, immunotherapy, genome mapping and synthetic genome assembly. He has been significantly involved in patent applications relating to cloning (somatic cell nuclear transfer), stem cells, cancer immunotherapy / CAR-T cells, regenerative medicine, gene therapy, and monoclonal antibodies/novel antigen receptor proteins (IgNARs/VNARs). Additionally, he brings deep involvement in patent applications relating to controlled release / sustained release pharmaceutical formulations, genetic diagnosis, biomarkers and synthetic biology.
Experience has provided Nick with an insight into intellectual property issues of research institutions, pharmaceutical and biotechnology companies.
His practice ranges from drafting original patent applications and devising filing strategies to advising on intellectual property aspects of company mergers and acquisitions, including due diligence on intellectual property rights.
His European portfolio includes post-grant opposition proceedings at the EPO, contentious proceedings in other foreign jurisdictions, as well as obtaining Supplementary Protection Certificates for pharmaceuticals.
Year Joined Firm: c. 1992
Education/Alumni: University of Birmingham
Network Memberships: CIPA, EPI, AIPPI, FICPI, TIPLO, Biochemical Society
Last updated 21 october 2021
